Navigation Links
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Date:8/19/2007

ly well tolerated by the study participants with side effects consistent with those in the currently approved label. The company plans to present the data at a major medical meeting in the future.

About Breakthrough Pain

Breakthrough pain is a component of chronic pain that is characterized by its rapid onset, moderate to severe intensity, and relatively short duration. Breakthrough pain has an average onset of three to five minutes and typically lasts 30 to 60 minutes.

About FENTORA

FENTORA is indicated only for the management of breakthrough pain in patients with cancer who are already receiving and who are tolerant to opioid therapy, as described below in the FENTORA label, for their underlying persistent cancer pain. FENTORA incorporates a drug delivery system that generates transient changes in pH, which may optimize how well the tablet dissolves and how quickly the medicine passes across the lining of the cheek, or buccal mucosa. Serious adverse events associated with all opioids are respiratory depression (potentially leading to apnea or respiratory arrest), circulatory depression, hypotension, and shock. All patients should be followed for symptoms of respiratory depression. The most common (greater than or equal to 10 percent) adverse events observed in FENTORA cancer clinical trials were nausea, dizziness, vomiting, fatigue, headache, constipation, anemia, somnolence, and peripheral edema. Most adverse events were mild to moderate in severity. No attempt was made to correct for concomitant use of around-the-clock opioids or cancer-related symptoms. In addition, application site reactions were reported in nine percent of patients, tended to occur early on treatment, and resulted in treatment discontinuation in only two percent of patients. PHYSICIANS AND OTHER HEALTHCARE PROVIDERS MUST BECOME FAMILIAR WITH THE

IMPORTANT WARNINGS IN THIS LABEL.

FENTORA contains fentanyl, an opioid agonist and a Schedul
'/>"/>

SOURCE Cephalon, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4 5

Related medicine technology :

1. Cephalon Presents Positive Results for Fentora in Breakthrough Pain Associated with Neuropathic Conditions
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/30/2015)... OF PRUSSIA, Pa. , March 30, 2015 ... the European Medicines Agency (EMA) has started the ... Application (MAA) for its long-acting fusion protein linking ... Upon European Commission approval, rIX-FP will provide hemophilia ... well as the European Economic Area (EEA) countries, ...
(Date:3/30/2015)... , March 30, 2015  BioPharmX Corporation (OTCQB: ... development of novel drug delivery products to address ... today announced the appointment of Stephen Morlock ... veteran, to its board of directors.  Mr. Morlock,s ... to expand its national roll-out of Violet iodine, ...
(Date:3/30/2015)... 30, 2015 Beta-O2 ... as the company,s new chief executive officer. Dr. ... leading early stage Israeli venture capital firm. He is ... and vascular surgery.        (Logo: http://photos.prnewswire.com/prnh/20140910/705638) ... Sherpa Innoventures is Beta-O2,s newest investor, having participated in ...
Breaking Medicine Technology:European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients 2European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients 3European Medicines Agency Commences Review of CSL Behring's Regulatory Submission for rIX-FP for Hemophilia B Patients 4BioPharmX Corporation Appoints Stephen Morlock To Its Board Of Directors 2BioPharmX Corporation Appoints Stephen Morlock To Its Board Of Directors 3Beta-O2 Names Dr. Yuval Avni CEO 2Beta-O2 Names Dr. Yuval Avni CEO 3
... 5, 2011 Jennerex, Inc., a private clinical-stage ... of first-in-class targeted oncolytic products for cancer, and ... specialized in the development of immunotherapeutic products, today ... 2 clinical studies of JX-594 were presented in ...
... Pharmaceuticals, Inc. (NASDAQ: QCOR ) today announced preliminary ... The Company announced the preliminary metrics in advance of the ... Executive Officer of Questcor, will present on Tuesday, April 5, ... web cast of the presentation during or after the event, ...
Cached Medicine Technology:Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors 2Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors 3Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors 4Jennerex and Transgene Announce the Presentation of Positive Clinical Data of JX-594 in Patients With Liver Tumors 5Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 2Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 3Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 4Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 5Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 6Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 7Questcor Pharmaceuticals Announces Preliminary Operating Metrics for First Quarter 2011 8
(Date:3/30/2015)... 2015 According to a recently published ... repair market will continue to dominate the European soft ... due to increasing numbers of ventral hernias, and the ... “The significantly large market share represented by ventral hernia ... We’re seeing a growing use of expensive biologics,” explains ...
(Date:3/30/2015)... This report studies the global tumor ablation ... 2019. , Based on the type of technology, ... four major segments, namely radio-frequency, microwave, cryoablation and ... laser ablation) segments. Moreover, based on type of ... into three segments, namely, interventional radiology, surgery and ...
(Date:3/30/2015)... 2015 On March 19th, 2015, in ... of the Detroit Lions, LiveToBeSober.org hosted the “Fighting Addiction ... ministers and bishops as well as other civic leaders ... at the luncheon, including retired Detroit Lions wide receiver ... and two survivors of their own personal battles with ...
(Date:3/30/2015)... Pa. (PRWEB) March 30, 2015 ... the Halal certification for all current Epax® Ultra ... facility in Ålesund, Norway. The certification ensures the ... comply with the Islamic religious regulations for Halal. ... step in FMC’s efforts to further advance its ...
(Date:3/30/2015)... GenSight ®, provider of an Enterprise Portfolio ... The Forrester Wave™: Strategic Planning For The [Business Technology] ... positions GenSight as a leader and gave the company ... the analytics, corporate strategy, assessment, direction and life cycle ... the Leaders category. , According to the report: ...
Breaking Medicine News(10 mins):Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 2Health News:High Prices for Advanced Biologic Hernia Repair Technology Driving European Soft Tissue Reinforcement and Regeneration Market Growth 3Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 2Health News:The Global Tumor Ablation Market is Poised to Reach the Value of $462.0 Million in 2019 - MarketsandMarkets Released Recently 3Health News:LiveToBeSober.org Releases Highlight Reel of Substance Abuse Conference Keynote Speakers 2Health News:FMC Health and Nutrition Announces Halal Certification for Epax® Brand Omega-3 Ingredients 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3
... that ravaged medieval Europe has a weakness that could help ... a study published on Thursday. ,A bacterium known ... Death spread when people are bitten by an infected flea, ... coughing or sneezing. ,There are periodic natural outbreaks ...
... comes to some of today’s health issues, 100 percent ... related to certain diseases – concludes// a study by ... ability to reduce risk compared to their whole fruit/vegetable ... conducted the literature review. The researchers analyzed a variety ...
... heavily on alternative therapists who mistreat their patients sexually ... therapists said to exist in Britain and there are ... On the other hand, completely qualified medical practitioners who ... rules and guidelines regarding their relationship with their patients. ...
... have a longer average lifespan than most of the men ... where it is usually reported// that people live longer on ... social policy study published on Wednesday, healthy Israeli men live ... than men, average lifespan of 82.4 years, on par with ...
... A US government funded study finds that CT scans used ... to be replaced by MRI scans which are better in ... should now be passed to magnetic resonance imaging,” wrote Dr. ... in Australia in a note accompanying the study report. ...
... presentation into Japanese for an American client who wants to ... not many can undertake. //And all this from Chennai too! ... proving that it is possible. Specialising in providing software services ... on the dot and raking in millions of dollars in ...
Cached Medicine News:Health News:Scientists Find Potential Weakness In Plague Germ 2Health News:Benefits of Fruit and Vegetable Juices 2Health News:Cashing in on IT for Healthcare 2
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
Rsch color coded Guedel airways offer our best value on oropharyngeal airways. They uniquely combine color coding for size and flexible material without a premium price. Color coded airways are latex...
New - Color Coded Berman Airways. A simple idea makes size identification easier for you., ,Premium upgrade without a premium price. Color Coded Berman airways are latex-free., ,Plastic. Single use...
Plastic Economical Single use. Non-Sterile....
Medicine Products: